Clinical Trials Sponsored by Boehringer Mannheim

Total 2739 results

Boehringer Ingelheim

Completed

Asthma Biomarker Study

Asthma

United Kingdom
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Boehringer Ingelheim

Completed

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Neoplasms | Leukemia

Germany, France, Italy, Belgium, Czechia
Boehringer Ingelheim

Completed

Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 685509 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body

Healthy

Germany
Boehringer Ingelheim

Completed

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

United States, Canada, Turkey
Boehringer Ingelheim

Completed

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

Spain
Boehringer Ingelheim

Terminated

Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, United Kingdom, Netherlands, Ireland, Argentina, Poland, Mexico, Spain, Bulgaria, Chile, Germany, Ukraine, Portugal, Belgium, Canada, Greece, Hungary
Boehringer Ingelheim

Completed

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Hemorrhage

United States, Spain, United Kingdom, Norway, Taiwan, Israel, Belgium, Australia, Sweden, Singapore, Germany, Italy, New Zealand, Austria, Japan, Canada, Czechia, Portugal, Netherlands, Korea, Republic of, France, Poland, Colombia, Hong... and more
Boehringer Ingelheim

Completed

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Hypertension
Boehringer Ingelheim

Completed

An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects

HIV Infections | Metabolism, Lipids

Netherlands, United Kingdom
Boehringer Ingelheim

Completed

Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5

Hypertension

France, Switzerland, Italy, Germany, Hong Kong, Netherlands, South Africa, Spain, Taiwan, Denmark, Sweden, Finland, Ireland, Korea, Republic of, Malaysia, Norway
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan
Boehringer Ingelheim

Completed

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Austria, France, Germany, Hungary, Netherlands, Poland, Romania, United Kingdom
Boehringer Ingelheim

Completed

Safety Tolerability and Pharmacokinetic of BI 411034

Healthy

Germany
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
Boehringer Ingelheim

Completed

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

Healthy

Germany
Boehringer Ingelheim

Completed

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet

Healthy

South Africa
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Healthy

Japan
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use

Healthy

Japan
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
Boehringer Ingelheim

Terminated

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

Carcinoma, Non-Small-Cell Lung

United States, Georgia, Thailand
Boehringer Ingelheim

Completed

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Completed

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Pulmonary Disease, Chronic Obstructive

Austria, Germany, Canada, United States, Poland, Belgium, Portugal, United Kingdom, Australia, Denmark, New Zealand
Boehringer Ingelheim

Completed

Relative Bioavailability of 2 Oral Formulations of Nintedanib

Healthy

Germany
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Add-on to Micamlo BP Trial

Hypertension

Japan
Boehringer Ingelheim

Completed

BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

Pain, Postoperative | Tooth Diseases

United States
Boehringer Ingelheim

Completed

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

Venous Thromboembolism

Canada, France, Russian Federation
Boehringer Ingelheim

Completed

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Carcinoma, Non-Small-Cell Lung

United States, Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain

Low Back Pain

Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Hepatitis C, Chronic

United States, Austria, Belgium, Canada, France, Germany, Japan, Portugal, Puerto Rico, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation

Hypertension
Boehringer Ingelheim

Completed

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Pulmonary Fibrosis

United States, Canada, Chile, China, Finland, France, Germany, Greece, India, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation, Spain, Turkey
Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Healthy

Belgium
Boehringer Ingelheim

Completed

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Hepatitis C, Chronic

United States, Canada, Germany
Boehringer Ingelheim

Completed

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Hepatitis C, Chronic
Boehringer Ingelheim

Completed

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Healthy

Germany
Boehringer Ingelheim

Terminated

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Boehringer Ingelheim

Completed

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

Healthy

Germany
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan

3

Subscribe